Stockscreener 앱 받기
0.00
100.00%
-4.34
시간 외 거래:
4.35
4.35
+
전일 마감가:
$4.34
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$37.54M
수익:
$2.74M
순이익/손실:
$-41.38M
주가수익비율:
0.00
EPS:
-5.08
순현금흐름:
$-31.10M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$4.5756
Lumos Pharma Inc Stock (LUMO) Company Profile
명칭
Lumos Pharma Inc
전화
512-215-2630
주소
4200 MARATHON BLVD., AUSTIN, TX
LUMO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LUMO
Lumos Pharma Inc
|
0.00 | 37.54M | 2.74M | -41.38M | -31.10M | -5.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Lumos Pharma Inc Stock (LUMO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-03-11 | 업그레이드 | Stifel | Hold → Buy |
| 2020-12-03 | 개시 | Cantor Fitzgerald | Buy |
| 2020-08-26 | 개시 | Piper Sandler | Overweight |
| 2020-08-17 | 재개 | ROTH Capital | Buy |
| 2020-08-04 | 개시 | H.C. Wainwright | Buy |
Lumos Pharma Inc 주식(LUMO)의 최신 뉴스
Pediatric Growth Hormone Deficiency Treatment Market Size - openPR.com
Halper Sadeh LLP, Martin Midstream Partners L.P., Lumos Pharma, Inc. - The Bradford Era
Hypopituitarism Market on Track for Major Expansion by 2032, - openPR.com
Advanced Micro Devices (AMD) Receives a Hold from Citi - The Globe and Mail
Hypopituitarism Market on Track for Major Expansion by 2032, According to DelveInsight | OPKO Health, Lumos Pharma, Versartis Inc., I-Mab Biopharma Co. Ltd - The Globe and Mail
Lucid Stock (LCID) Gains on Acquiring Bankrupt Nikola’s Assets - The Globe and Mail
Stocks in play: Wallbridge Mining Company Limited - The Globe and Mail
Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors - Business Wire
3 Reasons CHGG is Risky and 1 Stock to Buy Instead - The Globe and Mail
Apple (AAPL) Stock Trades Down, Here Is Why - The Globe and Mail
9 Amazing Tech Stocks Smart Investors Should Not Ignore - The Globe and Mail
Joseph Nigro Appointed to Eos Energy Enterprises Board of Directors - The Globe and Mail
Cleveland-Cliffs (CLF) Idles Steel Plant amid Soft Auto Market Demand - The Globe and Mail
One Vanguard Index Fund to Buy That May Beat the S&P 500 by 100% in the Next Few Years, According to a Wall Street Analyst - The Globe and Mail
BOSTON PIZZA ROYALTIES INCOME FUND ANNOUNCES FEBRUARY 2025 DISTRIBUTION - The Globe and Mail
Lumos expands deal for premmie birth test - The Australian
The Medulloblastoma Drug Global Market Report 2025: Detailed Market Analysis, Current Trends, Forecasts, And - EIN News
Pediatric Growth Hormone Deficiency Market to Expand - openPR
Advancements In Drug Development Technology Drives The Medulloblastoma Drug Market : Key Trend Transforming... - WhaTech
Buddying up: How small ASX healthcare stocks are teaming with giants for growth - Stockhead
1 No-Brainer Vanguard Index Fund to Buy Right Now for Less Than $500 - The Globe and Mail
Growth Hormone Deficiency Market Size to Reach USD 4.5 Billion by 2035, Impelled by Advancements in Early Detection - BioSpace
$HAREHOLDER ALERT FOR STAF, ATSG, GABC and ALTM: The M&A Class Action Firm Continues to Investigate the Merger - ACCESS Newswire
Infrared Imaging Microscope | Bruker Optics Inc. | Products - Photonics.com
Personal Finance - Business Wire
BRKR Stock Up on the Launch of LUMOS II ILIM QCL-Based IR Microscope - MSN
Bruker Launches Infrared Imaging Microscope for Pharma and Life Science Research - Marketscreener.com
Top 10 Oncology Capital Raises in the United States: December 2024 - Onco'Zine
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LUMO, ALTR, STAF on Behalf of Shareholders - The Eastern Progress Online
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MMLP and LUMO on Behalf of Shareholders - The Eastern Progress Online
Lumos Pharma Completes Merger and Delisting Process - TipRanks
Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures' Acquisition of Lumos Pharma - The Manila Times
Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures’ Acquisition of Lumos Pharma - Yahoo Finance
Lumos Pharma Completes Successful Tender Offer and Merger with Double Point Ventures - Nasdaq
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LUMO, BMTX, NXU on Behalf of Shareholders - The Eastern Progress Online
FirstGroup finalises $636m deal with Hitachi and Angel Trains - Railway Technology
Hepion Pharmaceuticals (NASDAQ:HEPA) Shares Down 4.1% – Here’s What Happened - Defense World
Lumos Pharma enters into definitive merger agreement with Double Point Ventures to go private via tender offer - substack.com
Global Human Growth Hormones Market to Reach USD 10 Billion by 2030 | DelveInsight - GlobeNewswire
Lumos Pharma Faces Uncertainty as CVRs Risk Expiring Worthless Post-Merger - MSN
LUMOLumos Pharma, Inc. Latest Stock News & Market Updates - StockTitan
Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 - GlobeNewswire
Lumos Pharma reports sustained growth in PGHD trials - Investing.com
Biopharma deal value, down for year, surges 72% in October - BioWorld Online
Favourable Signals For Lumos Diagnostics Holdings: Numerous Insiders Acquired Stock - Yahoo Finance
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LUMO, PIK, OB on Behalf of Shareholders - GlobeNewswire
Private Advisor Group, LLC Acquires Shares in Lumos Pharma Inc - GuruFocus.com
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger of STAF, ATSG, GABC and ALTM - AccessWire
Amgen Quickly Falls to Low, Down Over 4% on Obesity Data Concerns By Investing.com - Investing.com South Africa
$HAREHOLDER INVESTIGATION: The M&A Class Action Firm Reviews the Merger of STAF, ATSG, GABC and LUMO - AccessWire
Lumos: Q3 Earnings Snapshot - CT Insider
Lumos Pharma Inc (LUMO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.47%
2.63%
자본화:
|
볼륨(24시간):